Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America

Current Medical Research and Opinion

Volumn 32, Issue 3, 2016, Pages 427-439

  Lavalle González, Fernando J ^a   Eliaschewitz, Freddy G ^b   Cerdas, Sonia ^c   Del Pilar Chacon, Maria ^d   Tong, Cindy ^e   Alba, Maria ^e  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c Hospital CIMA   (Costa Rica)

^d Medicina Interna   (Colombia)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antihyperglycemic agent; Canagliflozin; Latin America; Phase 3 study; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENITAL CANDIDIASIS; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PHASE 3 CLINICAL TRIAL; SOUTH AND CENTRAL AMERICA; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LATIN AMERICA; MALE; METFORMIN; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84959194078     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1121865     Document Type: Article

References (24)

1. Guzman JR, Lyra R, Aguilar-Salinas CA, et al. Treatment of type 2 diabetes in Latin America: A consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association. Rev Panam Salud Publica 2010;28:463-71
2. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-49
3. Caballero AE. Type 2 diabetes in the Hispanic or Latino population: challenges and opportunities. Curr Opin Endocrinol Diabetes Obes 2007;14:151-7
4. The National Institutes of Health, National Eye Institute. Diabetic Retinopathy. Available at: https://nei.nih.gov/eyedata/diabetic#2 [Last accessed 24 September 2015]
5. United States Renal Data System. 2014 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014
6. Cusi K, Ocampo GL. Unmet needs in Hispanic/Latino patients with type 2 diabetes mellitus. Am J Med 2011;124:S2-9
7. Lorenzo C, Hanley AJ, Wagenknecht LE, et al. Relationship of insulin sensitivity, insulin secretion, and adiposity with insulin clearance in a multiethnic population: The insulin Resistance Atherosclerosis study. Diabetes Care 2013;36:101-3
8. Escalante M, Gagliardino JJ, Guzman JR, Tschiedel B. Call-to-action: timely and appropriate treatment for people with type 2 diabetes in Latin America. Diabetes Res Clin Pract 2014;104:343-52
9. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
10. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
11. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014;30:163-75
12. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hosp Pract 2013;41:72-84
13. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab 2015;17:294-303
14. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
15. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
16. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
17. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, Phase 3 study. Diabetes Care 2015;38:355-64
18. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013;56:2582-92
19. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract 2013;67:1267-82
20. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
21. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week, randomized trial. Diabetes Care 2013;36:2508-15
22. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72
23. Polidori D, Sha S, Ghosh A, et al. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:E867-71
24. Davidson J, Aguilar R, Lavalle-González F, et al. Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) by Hispanic/Latino ethnicity. Poster presented at: Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress; 14-18 May 2014; Las Vegas, NV, USA